Clinical study investigating Alex Therapeutics’ and Vicore’s standalone digital therapy (DTx) treating anxiety in patients with idiopathic pulmonary fibrosis (IPF) has launched in the US
· The DTx, Almee[TM], under clinical study was built on Alex Therapeutics proprietary “Alex DTx Platform”[1] · First clinical study with a digital therapy (DTx) in patients with IPF to address the psychological symptom burden in this disease · First patient enrolled in US pilot phase leading up to US pivotal phase of the study · The DTx is developed by Alex Therapeutics in collaboration with Vicore Pharma (”Vicore). Vicore is responsible for the clinical validation and commercialisation of the DTx Stockholm, April 21, 2022 - Alex Therapeutics, a Digital Therpautics (DTx) Software